Biomerica, Inc. (BMRA)

Biomerica, Inc. (BMRA) Healthcare & Pipeline Overview

Biomerica, Inc. specializes in diagnostic and therapeutic products for gastrointestinal diseases, food intolerances, and diabetes. With a focus on developing and marketing diagnostic test kits and therapies like InFoods, the company serves physicians' offices, drugstores, and laboratories, positioning itself in the medical device sector.

What Is the Investment Thesis for BMRA?

Biomerica, Inc. presents a speculative investment opportunity within the medical device sector. The company's focus on gastrointestinal diagnostics and therapeutics, particularly the InFoods IBS therapy, could drive future revenue growth if clinical trials and market adoption are successful. However, the company's negative profit margin of -96.5% and small market capitalization of $5.32M indicate substantial financial risks. The low beta of 0.28 suggests lower volatility compared to the broader market, but this does not mitigate the underlying financial challenges. A successful commercialization of InFoods and expansion of COVID-19 diagnostic products could serve as catalysts. Investors should closely monitor the company's ability to improve profitability and manage its operational expenses.

Based on FMP financials and quantitative analysis

BMRA Key Highlights

• Market capitalization of $5.32M, indicating a small-cap company with potential for high growth but also higher risk.
• Negative profit margin of -96.5%, highlighting significant challenges in achieving profitability.
• Gross margin of 4.3%, suggesting limited ability to generate profit from sales after accounting for the cost of goods sold.
• Beta of 0.28, indicating lower volatility compared to the overall market.
• Focus on gastrointestinal diseases, food intolerances, diabetes, and COVID-19, positioning the company in areas with significant market demand.

Who Are BMRA's Competitors?

BMRA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BMRA's Key Strengths?

• Specialized focus on gastrointestinal diagnostics and therapeutics.
• Development of innovative diagnostic-guided therapies like InFoods.
• Established relationships with key distribution channels.
• Patented products and technologies.

What Are BMRA's Weaknesses?

• Negative profit margin and limited profitability.
• Small market capitalization and limited financial resources.
• Dependence on successful commercialization of new products.
• Limited brand recognition compared to larger competitors.

What Could Drive BMRA Stock Higher?

• Clinical trial results for InFoods IBS therapy.
• Expansion of COVID-19 diagnostic product sales.
• Development and commercialization of new gastrointestinal diagnostic tests.

What Are the Key Risks for BMRA?

• Financial-distress signal — its Altman Z-Score of -15.23 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-98.1%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Unsuccessful clinical trials for InFoods.
• Intense competition in the COVID-19 diagnostics market.
• Regulatory hurdles and lengthy approval processes.
• Limited financial resources and profitability challenges.

What Are the Growth Opportunities for BMRA?

• InFoods IBS Therapy: Biomerica's development of InFoods, a diagnostic-guided therapy for Irritable Bowel Syndrome (IBS), represents a significant growth opportunity. The global IBS market is expected to reach billions of dollars by 2027, driven by increasing awareness and diagnosis rates. Successful clinical trials and subsequent commercialization of InFoods could provide a substantial revenue stream for Biomerica. The company's diagnostic-guided approach offers a competitive advantage by tailoring treatment to individual patient needs.
• COVID-19 Diagnostic Products: The ongoing demand for COVID-19 diagnostic testing presents a near-term growth opportunity for Biomerica. As new variants emerge and testing remains a crucial tool for managing the pandemic, Biomerica's diagnostic products can contribute to revenue growth. The company can leverage its existing manufacturing and distribution infrastructure to capitalize on this demand. However, competition in the COVID-19 diagnostics market is intense, requiring Biomerica to differentiate its products through accuracy, speed, or cost-effectiveness.
• Expansion of Gastrointestinal Diagnostic Portfolio: Biomerica can expand its portfolio of diagnostic tests for gastrointestinal diseases to capture a larger share of this market. The increasing prevalence of conditions like Crohn's disease, ulcerative colitis, and celiac disease drives demand for accurate and reliable diagnostic tools. By developing and commercializing new tests that address unmet needs, Biomerica can strengthen its position in the gastrointestinal diagnostics market. This includes exploring advanced technologies like molecular diagnostics and biomarkers.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with pharmaceutical companies, research institutions, and healthcare providers can accelerate Biomerica's growth. Collaborations can provide access to new technologies, markets, and funding opportunities. For example, partnering with a pharmaceutical company developing IBS drugs could enhance the commercial potential of InFoods. Strategic alliances can also help Biomerica expand its geographic reach and distribution network.
• Direct-to-Consumer (DTC) Marketing: Biomerica can explore direct-to-consumer marketing strategies to increase awareness and adoption of its diagnostic tests, particularly for conditions like food intolerances. By offering convenient and accessible testing options directly to consumers, Biomerica can tap into a growing market of individuals seeking proactive health management. This approach requires compliance with regulatory requirements and careful consideration of ethical and privacy concerns.

What Opportunities Does BMRA Have?

• Growing market for gastrointestinal diagnostics and therapeutics.
• Increasing demand for personalized medicine and diagnostic-guided therapies.
• Expansion into new geographic markets.
• Strategic partnerships and collaborations.

What Threats Does BMRA Face?

• Intense competition from larger medical device companies.
• Stringent regulatory requirements and lengthy approval processes.
• Risk of unsuccessful clinical trials and product development.
• Economic downturns and healthcare spending cuts.

What Are BMRA's Competitive Advantages?

• Patented diagnostic and therapeutic products.
• Specialized focus on gastrointestinal diseases and food intolerances.
• Development of diagnostic-guided therapies like InFoods.
• Established relationships with physicians' offices, drugstores, and laboratories.

What Does BMRA Do?

Biomerica, Inc., established in 1971 and headquartered in Irvine, California, is a biomedical technology company focused on developing, patenting, manufacturing, and marketing diagnostic and therapeutic products. The company's core business revolves around creating diagnostic test kits that analyze blood, urine, or fecal specimens to detect various medical conditions and diseases. These kits measure specific bacteria, hormones, antibodies, antigens, and other substances present in the body, aiding in the diagnosis of gastrointestinal diseases, food intolerances, diabetes, and other esoteric conditions. Biomerica primarily targets physicians' offices, over-the-counter drugstores, and hospital/clinical laboratories as its primary sales channels. Biomerica's product portfolio includes diagnostic tests and therapeutic solutions, with a significant emphasis on gastrointestinal health. The company is actively developing InFoods, an irritable bowel syndrome (IBS) therapy technology coupled with diagnostic-guided therapy. Additionally, Biomerica offers Helicobacter pylori products and has expanded its offerings to include diagnostic products for COVID-19 infection. The company's long-standing presence in the medical device industry underscores its commitment to innovation and addressing unmet medical needs through advanced diagnostic and therapeutic solutions. With 64 employees, Biomerica continues to focus on expanding its product line and market reach within the global healthcare landscape.

What Products and Services Does BMRA Offer?

• Develops diagnostic test kits for analyzing blood, urine, and fecal specimens.
• Manufactures and markets diagnostic and therapeutic products.
• Focuses on detection and treatment of medical conditions and diseases.
• Offers products for gastrointestinal diseases, food intolerances, and diabetes.
• Develops diagnostic-guided therapies like InFoods for Irritable Bowel Syndrome (IBS).
• Provides diagnostic products for COVID-19 infection.
• Sells products to physicians' offices, over-the-counter drugstores, and hospital/clinical laboratories.

How Does BMRA Make Money?

• Develops and manufactures diagnostic test kits and therapeutic products.
• Sells products directly to physicians' offices, drugstores, and laboratories.
• Generates revenue through the sale of diagnostic tests and therapies for various medical conditions.

What Industry Does BMRA Operate In?

Biomerica operates within the medical device industry, a sector characterized by continuous innovation and stringent regulatory requirements. The global medical device market is projected to reach trillions of dollars by 2026, driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. Biomerica's focus on gastrointestinal diagnostics and therapeutics aligns with the growing demand for personalized medicine and minimally invasive diagnostic procedures. Competition includes established players and smaller, specialized firms. Biomerica's success depends on its ability to differentiate its products, secure regulatory approvals, and effectively market its solutions to healthcare providers and patients.

Who Are BMRA's Key Customers?

• Physicians' offices
• Over-the-counter drugstores
• Hospital/clinical laboratories
• Patients seeking diagnostic tests and therapies

Company Profile

Biomerica, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Irvine, US. The company is led by CEO Zackary S. Irani. BMRA has traded publicly since 1984.

ROE -98%Key Financial Metrics

Return on equity for Biomerica, Inc. stands at -98.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -85.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -58.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.64 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -78.8%, the inverse of the P/E and a quick read on earnings relative to price.

BMRA Valuation & Market Position

With a $5.32M market cap, Biomerica, Inc. sits in the micro-cap segment of the market. Relative to its peer group, BMRA's quantitative score of 19/100 is below the peer average of 69/100.

Quarterly Financial Performance: Biomerica, Inc.

Revenue for Biomerica, Inc. came in at $987K during Q1 2026, a 18.4% contraction versus the preceding quarter. The company recorded a net loss of $1.3M, with diluted EPS of $-0.44. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, BMRA averaged $-0.26 in diluted EPS.

F-Score 3/9Financial Health

Biomerica, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.23 places it in the distress zone, a signal of elevated financial risk.

BMRA Financials

BMRA Latest News

BMRA Analyst Consensus

BMRA MoonshotScore

BMRA Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources